DGAP-Ad hoc: Biotest AG Vz.

DGAP-Adhoc: Biotest AG: Altered Tax Assessments for 2005 - 2008

Biotest AG / Key word(s): Legal Matter

03.08.2016 18:15

Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR)

Altered Tax Assessments for 2005 - 2008

Dreieich, 3 August 2016. Today the Finanzamt Offenbach am Main (tax office Offenbach am Main) served to Biotest AG altered tax assessments for corporate tax, solidarity tax and trade tax for the years 2005 until 2008. The alterations are based on the investigations by the tax authorities and the public prosecutor in connection with the Russia business of Biotest AG. This leads to liabilities for tax and interest totalling to approx. EUR 20 million.

The company will have the tax assessments evaluated by their tax consultants. According to our first appraisal this approach by the financial authorities is conflicting with recently published decisions by the Bundesfinanzhof (Federal Fiscal Court) on the tax deduction of operating expenses.

Biotest Aktiengesellschaft Board of Management

Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.de

Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,300 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact Dr. Monika Buttkereit phone: +49-6103-801-4406 email: investor_relations@biotest.de

PR contact Dirk Neumüller phone: +49-6103-801-269 email: pr@biotest.de

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 Preference shares: securities' ID No. 522723; ISIN DE0005227235 Listing: Prime Standard Open Market: Berlin, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart

03.08.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

--------------------------------------------------------------------------- Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------